Latest Advances in Lung Cancer Research

Study indicates advanced lung cancer patients may stop immunotherapy after 2 years without impacting survival, requiring further research for confirmation.

Adagrasib shows promise in treating KRAS G12C-mutant NSCLC, with lasting responses and potential as a much-needed targeted therapy.

The FDA granted orphan drug status to Quratusugene ozeplasmid, a promising gene-based therapy for small cell lung cancer, to expedite its development.

New treatments like immunotherapy and targeted therapy are improving post-surgery outcomes for lung cancer, with research ongoing to optimize these methods.

The inflammation associated with lung cancer and depression may impact survival, despite treatments like immunotherapy and targeted therapies.

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

Research study shows pacritinib has the ability to selectively target in squamous cell but does not impact normal glucose metabolism.

Removing only a portion of lobes is as effective as the traditional surgery for some patients with early-stage lung cancer.

The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies.

Amgen’s Lumakras cut the risk of disease progression or death by 34% compared with the chemotherapy docetaxel in previously treated KRAS G12C-mutated non-small cell lung cancer.

Fox Chase Cancer Center highlights advances in NSCLC treatment with immunotherapy and the promise of amivantamab for specific genetic mutations, alongside ongoing SCLC research.